{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:57:08Z","timestamp":1761101828287},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2008,3,25]],"date-time":"2008-03-25T00:00:00Z","timestamp":1206403200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1007\/s12032-007-9030-2","type":"journal-article","created":{"date-parts":[[2008,3,24]],"date-time":"2008-03-24T13:53:07Z","timestamp":1206366787000},"page":"274-278","source":"Crossref","is-referenced-by-count":14,"title":["Oral premedication for the prevention of hypersensitivity reactions to paclitaxel"],"prefix":"10.1007","volume":"25","author":[{"given":"Jamal","family":"Zidan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Hussein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Abzah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Tamam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z.","family":"Farraj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,3,25]]},"reference":[{"key":"9030_CR1","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1093\/jnci\/82.15.1247","volume":"82","author":"EK Rowinsky","year":"1990","unstructured":"Rowinsky EK, Cazenave LA, Donehower RC. Taxol: a novel investigational antineoplastic agent. J Natl Cancer Inst 1990;82:1247\u201359.","journal-title":"J Natl Cancer Inst"},{"key":"9030_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","volume":"334","author":"WP McGuire","year":"1996","unstructured":"McGuire WP, et\u00a0al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. N Engl J Med 1996;334:1\u20136.","journal-title":"N Engl J Med"},{"issue":"1","key":"9030_CR3","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3816\/CBC.2000.n.002","volume":"1","author":"JA Sparano","year":"2000","unstructured":"Sparano JA. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials. Clin Breast Cancer 2000;1(1):32\u201340.","journal-title":"Clin Breast Cancer"},{"key":"9030_CR4","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1081\/CNV-120005919","volume":"21","author":"GR Simon","year":"2003","unstructured":"Simon GR, Bunn PA. Jr. Taxanes in the treatment of advanced (stages II and IV) non-small cell lung cancer (NSCLC): recent developments. Cancer Invest 2003;21:87\u2013104.","journal-title":"Cancer Invest"},{"issue":"3 Suppl 2","key":"9030_CR5","first-page":"7","volume":"11","author":"EK Rowinsky","year":"1997","unstructured":"Rowinsky EK. The taxanes: dosing and scheduling considerations. Oncology (Williston Park) 1997;11(3 Suppl 2):7\u201319.","journal-title":"Oncology (Williston Park)"},{"issue":"Suppl 17","key":"9030_CR6","first-page":"69","volume":"24","author":"AY Chang","year":"1997","unstructured":"Chang AY, Boros L, Asbury R, Hui L, Rubins J. Dose-escalation study of weekly 1-hour paclitaxel administration in patients with refractory cancers. Semin Oncol 1997;24 (Suppl 17):69\u201371.","journal-title":"Semin Oncol"},{"issue":"4 Suppl 3","key":"9030_CR7","first-page":"1","volume":"20","author":"EK Rowinsky","year":"1993","unstructured":"Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC. Clinical toxicities encountered with paclitaxel. Semin Oncol 1993;20 (4 Suppl 3):1\u201315.","journal-title":"Semin Oncol"},{"key":"9030_CR8","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1200\/JCO.1990.8.7.1263","volume":"7","author":"RB Weiss","year":"1990","unstructured":"Weiss RB, et\u00a0al. Hypersensitivity reaction from taxol. J Clin Oncol 1990;7:1263\u20138.","journal-title":"J Clin Oncol"},{"key":"9030_CR9","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1006\/gyno.1997.4906","volume":"68","author":"JK Olson","year":"1998","unstructured":"Olson JK, et\u00a0al. Taxol hypersensitivity: rapid retreatment is safe and cost effective. Gynecol Oncol 1998;68:25\u20138.","journal-title":"Gynecol Oncol"},{"issue":"Suppl 19","key":"9030_CR10","first-page":"13","volume":"69","author":"MA Bookman","year":"1997","unstructured":"Bookman MA, Kloth DD, Kover PE, Sanolinsky S, Ozole RF. Intravenous prophylaxis for paclitaxel-related hypersensitivity reactions. Semin Oncol 1997;69(Suppl 19):13\u20135.","journal-title":"Semin Oncol"},{"key":"9030_CR11","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1023\/A:1008207025430","volume":"8","author":"MA Bookman","year":"1997","unstructured":"Bookman MA, Kloth DD, Kover PE, Sanolinsky S, Ozole RF. Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions. Ann Oncol 1997;8:611\u20134.","journal-title":"Ann Oncol"},{"issue":"5\u20136","key":"9030_CR12","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1081\/CNV-120003535","volume":"20","author":"J Quock","year":"2002","unstructured":"Quock J, et\u00a0al. Premedication strategy for weekly paclitaxel. Cancer Invest 2002;20(5\u20136):666\u201372.","journal-title":"Cancer Invest"},{"key":"9030_CR13","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1200\/JCO.1996.14.4.1071","volume":"14","author":"B Reckzeh","year":"1996","unstructured":"Reckzeh B, et\u00a0al. Severe lymphocytopenia and interstitial pneumonia in patients treated with paclitaxel and simultaneous radiotherapy for non-small-cell lung cancer. J Clin Oncol 1996;14:1071\u20136.","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"9030_CR14","first-page":"117","volume":"9","author":"D Lau","year":"1999","unstructured":"Lau D, et\u00a0al. Concurrent twice-weekly paclitaxel and thoracic irradiation for stage III non-small cell lung cancer. Semin Rad Oncol 1999;9(Suppl 1):117\u2013120.","journal-title":"Semin Rad Oncol"},{"key":"9030_CR15","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1365-2125.1983.tb01501.x","volume":"15","author":"G Taylor","year":"1983","unstructured":"Taylor G, Houston JB, Shaffer J, Mawer G. Pharmacokinetics of promethazine and its sulphoxide metabolite after intravenous and oral administration to man. Br J Clin Pharmacol 1983;15:287\u201393.","journal-title":"Br J Clin Pharmacol"},{"key":"9030_CR16","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2165\/00003088-198510060-00002","volume":"10","author":"DM Paton","year":"1985","unstructured":"Paton DM, Webster DR. Clinical pharmacokinetics of H (1)-receptor antagonists (the antihistamines). Clin Pharmacokinet 1985;10:477\u201397.","journal-title":"Clin Pharmacokinet"},{"key":"9030_CR17","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1200\/JCO.2000.18.19.3409","volume":"18","author":"JRA Ioannidis","year":"2000","unstructured":"Ioannidis JRA, Hesketh PJ, Lau J. Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: a meta-analysis of randomized evidence. J Clin Oncol 2000;18:3409\u201322.","journal-title":"J Clin Oncol"},{"key":"9030_CR18","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1200\/JCO.2000.18.1.102","volume":"18","author":"M Markman","year":"2000","unstructured":"Markman M, et\u00a0al. Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center. J Clin Oncol 2000;18:102\u20135.","journal-title":"J Clin Oncol"},{"key":"9030_CR19","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1200\/JCO.1993.11.5.885","volume":"5","author":"DM Peereboom","year":"1993","unstructured":"Peereboom DM, et\u00a0al. Successful re-treatment with taxol after major hypersensitivity reactions. J Clin Oncol 1993;5:885\u201390.","journal-title":"J Clin Oncol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-007-9030-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-007-9030-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-007-9030-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T02:22:33Z","timestamp":1559442153000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-007-9030-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3,25]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["9030"],"URL":"https:\/\/doi.org\/10.1007\/s12032-007-9030-2","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,3,25]]}}}